Top Page
Mesoblast Limited
(Sydney:MSB)
Mesoblast Limited (MSB) vs. iShares MSCI Australia ETF (EWA)
Mesoblast Limited Business Overview & Revenue Model
Mesoblast Limited Earnings Call Summary
Mesoblast Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.67M | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M |
| Gross Profit | -22.57M | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M |
| EBITDA | -49.42M | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M |
| Net Income | -103.35M | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M |
Balance Sheet | ||||||
| Total Assets | 687.31M | 669.15M | 669.41M | 662.14M | 744.72M | 733.60M |
| Cash, Cash Equivalents and Short-Term Investments | 77.07M | 62.56M | 70.92M | 60.03M | 136.88M | 129.33M |
| Total Debt | 99.72M | 118.92M | 116.50M | 106.91M | 105.50M | 99.31M |
| Total Liabilities | 168.58M | 188.80M | 167.58M | 165.10M | 163.32M | 184.28M |
| Stockholders Equity | 518.73M | 480.36M | 501.84M | 497.04M | 581.40M | 549.33M |
Cash Flow | ||||||
| Free Cash Flow | -21.07M | -48.79M | -63.58M | -66.01M | -108.33M | -58.61M |
| Operating Cash Flow | -20.66M | -48.46M | -63.27M | -65.78M | -106.68M | -56.37M |
| Investing Cash Flow | 327.50K | -97.00K | -194.00K | -232.00K | -1.65M | -3.27M |
| Financing Cash Flow | 4.58M | 40.25M | 74.50M | -9.87M | 114.47M | 137.04M |
Mesoblast Limited Technical Analysis
Mesoblast Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.58B | 11.28 | 51.39% | ― | -8.06% | -10.13% | |
75 Outperform | $473.17M | 12.19 | 19.93% | 0.50% | 12.74% | 27.56% | |
60 Neutral | HK$15.46B | 5.45 | -7.43% | 6.25% | 11.72% | -20.69% | |
56 Neutral | AU$35.43M | ― | -36.95% | ― | ― | 11.11% | |
49 Neutral | $2.00B | ― | -21.31% | ― | ― | ― | |
44 Neutral | $328.59M | ― | -31.16% | ― | ― | 14.47% | |
44 Neutral | AU$266.46M | ― | -29.77% | ― | 6.07% | 59.09% |
Mesoblast Limited Corporate Events
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the biopharmaceutical industry. This change in holding reflects a series of transactions involving the purchase, sale, and lending of securities, which resulted in a decrease in their voting power in the company.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have become substantial holders in the company, holding a 5.06% voting power with 64,614,620 ordinary shares. This development indicates a significant investment by JPMorgan, which could influence Mesoblast’s market dynamics and stakeholder interests, highlighting the strategic importance of this financial backing in the company’s future operations.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of June 11, 2025. This change in substantial holding involves various transactions and securities lending agreements managed by JPMorgan’s subsidiaries, impacting the voting securities of Mesoblast Limited. The cessation of JPMorgan’s substantial holding could influence Mesoblast’s shareholder dynamics and market perception.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has reported progress with the FDA on the accelerated approval pathway for its product Revascor® in treating ischemic chronic heart failure and a label extension for Ryoncil® in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). The company held a Type B meeting with the FDA to discuss a potential Biologics License Application for Revascor® and plans a meeting in July to discuss a pivotal trial for Ryoncil® in adults. Ryoncil® has been commercially available in the U.S. since March 2025, with significant uptake and coverage expansion, indicating strong market acceptance and potential growth in the cellular medicine industry.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
The Vanguard Group has become a substantial holder in Mesoblast Limited, acquiring a 5.004% voting power with 63,941,083 ordinary shares. This significant investment by a major global asset manager could enhance Mesoblast’s market credibility and attract further interest from investors, potentially impacting its stock performance and strategic positioning in the biotechnology sector.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.30 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have become substantial holders in the company, with a 5.06% voting power through various securities holdings and agreements. This development indicates a significant investment by JPMorgan, potentially impacting Mesoblast’s market position and signaling confidence in the company’s future prospects.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced a substantial holding update, indicating significant voting power and relevant interests held by various entities, including State Street Corporation and its subsidiaries. The update highlights the extensive involvement of institutional investors and financial entities in the company’s shares, which may influence Mesoblast’s market dynamics and stakeholder interests.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has received a seven-year orphan-drug exclusive approval from the FDA for its product Ryoncil® (remestemcel-L), used in treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. This exclusivity prevents the approval of similar mesenchymal stromal or stem cell products for the same indication during this period. Additionally, Mesoblast holds biologic exclusivity until December 2036, protecting against biosimilar market entry. These exclusivities, combined with Mesoblast’s strong intellectual property portfolio, provide a significant commercial barrier to competitors, reinforcing the company’s market position and offering long-term protection in major markets.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.40 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Mesoblast Limited, acquiring a 5.03% voting power in the company as of May 9, 2025. This development may influence Mesoblast’s market positioning and stakeholder interests, as JPMorgan’s involvement could bring increased financial scrutiny and potential strategic opportunities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be a substantial holder in the company. This change in substantial holding involves various transactions, including securities lending and proprietary trading, which have impacted the voting securities of Mesoblast Limited. The cessation of JPMorgan’s substantial holding may influence the company’s market perception and stakeholder dynamics.
Mesoblast Limited, a company involved in the biotechnology sector, announced a change in substantial holding as State Street Corporation and its subsidiaries ceased to be substantial holders. This change in substantial holding may impact Mesoblast’s shareholder composition and influence its market positioning, as State Street Corporation’s involvement in voting securities has altered.
Mesoblast Limited has announced a new substantial holder, Aware Super Pty Ltd, which has acquired a significant voting power in the company. This change in substantial holding may impact Mesoblast’s strategic decisions and influence its market position, as the new holder has the power to control voting rights and securities disposal.
Mesoblast Limited announced the commercial availability of Ryoncil® (remestemcel-L) for treating children with acute GVHD in the U.S., following FDA approval. The company is expanding its reach with plans to onboard more transplant centers and increase insurance coverage. Additionally, Mesoblast is progressing with its Revascor® and rexlemestrocel-L therapies, with ongoing FDA discussions and trials aimed at addressing chronic heart failure and low back pain, respectively. The company also strengthened its financial position with a successful global private placement and enhanced its board of directors.
Mesoblast Limited announced the appointment of Lyn Cobley as a new director, effective April 29, 2025. Cobley holds 33,000 ordinary shares through Synergy Finance Pty Ltd as trustee for Cobley Superfund. This appointment may influence the company’s strategic direction and stakeholder confidence, given Cobley’s experience and interests in the company.
Mesoblast Limited has appointed Lyn Cobley, a seasoned leader in the financial services industry, to its Board of Directors. This strategic move follows the recent FDA approval of RYONCIL and aims to bolster Mesoblast’s commercialization efforts and expansion into new indications for prevalent diseases. Cobley’s extensive experience in corporate finance and governance is expected to enhance Mesoblast’s strategic leadership as it continues to develop and commercialize its cell therapy products.
Mesoblast Limited has announced a change in the director’s interest, specifically involving Gregory George. The change includes the acquisition of 50,000 American Depositary Shares (ADS) and the expiry of a put option over the same amount. This update reflects ongoing adjustments in the company’s director-level securities holdings, which could influence stakeholder perceptions and the company’s market dynamics.
Mesoblast has successfully expanded the coverage of its FDA-approved therapy, Ryoncil, to over 100 million insured lives in the United States. This expansion includes Medicaid and commercial payers, highlighting the therapy’s growing acceptance and potential impact on treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The increased coverage is expected to enhance Mesoblast’s market position and provide broader access to its innovative treatment, potentially benefiting stakeholders and patients alike.
Mesoblast Limited has announced the cessation of 30,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting the challenges in meeting certain operational conditions.
Mesoblast Limited has announced the issuance of over 8 million ordinary fully paid securities, which were issued on March 27, 2025. This move is part of the company’s ongoing efforts to manage its equity securities, potentially impacting its market positioning and providing new opportunities for stakeholders.
Mesoblast Limited announced the quotation of 7,255,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.
Mesoblast Limited announced the issuance of 7,275,000 unquoted equity securities as part of an employee incentive scheme. This move is likely to impact the company’s financial structure and could enhance employee motivation, potentially influencing the company’s market position and stakeholder interests.
Mesoblast Limited has announced a change in the interest of its director, Dr. Silviu Itescu, in the company’s securities. The change involves the acquisition of 3,108,000 options, bringing the total number of options held by Dr. Itescu to 16,449,558, following shareholder approval at the 2024 Annual General Meeting. This adjustment in director’s interest reflects the company’s ongoing governance and shareholder engagement practices, potentially impacting investor perceptions and the company’s market dynamics.
Mesoblast Limited has announced the issuance of 4,839,000 unquoted equity securities, specifically options expiring on various dates and at various prices, as part of an employee incentive scheme. This strategic move aims to align employee interests with company performance, potentially enhancing operational efficiency and stakeholder value in the competitive biotechnology sector.
Mesoblast Limited announced that its allogeneic cellular products, including Ryoncil and Revascor, are designated as ‘U.S. Country of Origin’ and will not be subject to U.S. tariffs on imported products. This designation, based on the products being manufactured from U.S. donors, allows Mesoblast to avoid potential cost increases and maintain competitive pricing in the U.S. market, potentially strengthening its position in the industry and providing reassurance to stakeholders about the stability of its operations.
Mesoblast Limited has filed a request for a Type B meeting with the FDA to discuss the accelerated approval pathway for its product Revascor, intended for treating ischemic chronic heart failure with reduced ejection fraction and inflammation. This meeting, expected to occur this quarter, aims to obtain FDA feedback on chemistry, manufacturing, and controls, as well as alignment on potency assays and the design of a confirmatory trial. The outcome of this meeting could significantly impact Mesoblast’s operations by potentially expediting the approval process for Revascor, thereby enhancing its industry positioning and offering new treatment options for patients with heart failure.
Mesoblast Limited has announced its entry into the Medicaid National Drug Rebate Agreement with the U.S. Centers for Medicare & Medicaid Services for its product Ryoncil, providing access to children covered by Medicaid with steroid-refractory acute graft versus host disease (SR-aGvHD). This development marks a significant commercial milestone for Mesoblast, as it ensures that Ryoncil is available to all U.S. children with SR-aGvHD, regardless of their insurance status, potentially enhancing the company’s market position and impact on stakeholders.
Mesoblast Limited has announced the commercial availability of Ryoncil® (remestemcel-L) in the United States, marking a significant milestone as the first FDA-approved mesenchymal stromal cell (MSC) therapy for any indication. Ryoncil® is designed to treat pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. Mesoblast has established a patient access hub, MyMesoblast™, to assist with insurance coverage and financial assistance, ensuring broad access to this potentially life-saving therapy. The company is actively engaging with insurers to expand coverage, with nine commercial payers already on board, covering approximately 37 million lives in the U.S. This development reflects Mesoblast’s commitment to delivering innovative cellular medicines to patients in need.